Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.

Saved in:
Bibliographic Details
Title: Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
Authors: Meraz IM; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. imeraz@mdanderson.org., Majidi M; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fang B; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meng F; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao L; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shao R; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song R; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li F; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lissanu Y; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ha MJ; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Korea., Wang Q; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shpall E; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jung SY; Department of Biochemistry, Baylor College of Medicine, Houston, TX, USA., Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Gui P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Riess JW; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA., Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Communications biology [Commun Biol] 2023 Jun 06; Vol. 6 (1), pp. 608. Date of Electronic Publication: 2023 Jun 06.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2399-3642
DOI:10.1038/s42003-023-04979-9